enGene Therapeutics Inc. ENGN
Set alert
1.47 USD +0.02 +1.03%
As of Nov 3, 11:20 AM ET
1.45 Day range 1.50
1.40 52-week range 12.25
- YTD
- -83.78%
- 1 year
- -78.83%
- Open
- 1.47
- Prev close
- 1.45
- Mkt cap
- 98.18M
- Vol
- 152.88K
- Avg vol
- 758.86K
- EPS
- -2.07
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.45
- High
- 1.50
- Forward P/E
- -3.53
- Beta
- -0.76
- Short ratio
- 11.39
- Inst. own
- 83.23%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 8.10
- 200-d avg
- 10.01
- 1y target
- 27.00
6M chart
Signals (30)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 14, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 4 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 4 weeks ago |
| SMA: Bullish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
Newest 20 of 30.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +1743.0% upside
Now 1.47
- Target (low)
- 16.00
- Target (mean)
- 27.00
- Target (high)
- 37.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy4
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 8
- 2 months ago 6
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.3825 | -0.43 – -0.31 | -0.46 | +16.9% | 0 | 0.0% | 8 |
| Next quarter | -0.4025 | -0.45 – -0.32 | -0.38 | -5.9% | 0 | 0.0% | 8 |
| Current year | -1.62 | -1.84 – -1.30 | -1.46 | -11.2% | 0 | 0.0% | 9 |
| Next year | -2.01 | -2.28 – -1.57 | -1.62 | -24.1% | 7.17M | 0.0% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Dec 23, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 6, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 27, 2024 | Raymond James | Initiated | — | Outperform |
| Nov 18, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Sep 24, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Sep 11, 2024 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 28, 2024 | Oppenheimer | Initiated | — | Outperform |
| Apr 22, 2024 | Wells Fargo | Initiated | — | Overweight |
| Apr 15, 2024 | Guggenheim | Initiated | — | Buy |
| Mar 28, 2024 | UBS | Initiated | — | Buy |
| Mar 8, 2024 | Morgan Stanley | Initiated | — | Overweight |